Skip to content
10-K

Annual Report

iTeos Therapeutics, Inc.

0000950170-25-033066

← back to feed
Filed
Mar 5, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 28, 2025 38.19M sh
Shares Diluted FY 2024 · Dec 31, 2024 40.47M sh
Shares Diluted FY 2024 · Dec 31, 2023 35.76M sh
Capex FY 2024 · Dec 31, 2024 $1.63M
Capex FY 2024 · Dec 31, 2023 $2.97M
Operating Cash Flow FY 2024 · Dec 31, 2024 −$98.18M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$103.76M
Short Term Investments FY 2024 · Dec 31, 2024 $352.52M
Short Term Investments FY 2024 · Dec 31, 2023 $280.74M
Cash And Equivalents FY 2024 · Dec 31, 2024 $142.13M
Cash And Equivalents FY 2024 · Dec 31, 2023 $251.18M
Stockholders Equity FY 2024 · Dec 31, 2024 $590.29M
Stockholders Equity FY 2024 · Dec 31, 2023 $575.23M
Stockholders Equity FY 2024 · Dec 31, 2022 $663.33M
Current Liabilities FY 2024 · Dec 31, 2024 $40.36M
Current Liabilities FY 2024 · Dec 31, 2023 $40.01M
Total Liabilities FY 2024 · Dec 31, 2024 $96.68M
Total Liabilities FY 2024 · Dec 31, 2023 $92.36M
Current Assets FY 2024 · Dec 31, 2024 $509.54M
Current Assets FY 2024 · Dec 31, 2023 $550.65M
Total Assets FY 2024 · Dec 31, 2024 $686.98M
Total Assets FY 2024 · Dec 31, 2023 $667.59M
Eps Diluted FY 2024 · Dec 31, 2024 −$3.32
Eps Diluted FY 2024 · Dec 31, 2023 −$3.15
Eps Basic FY 2024 · Dec 31, 2024 −$3.32
Eps Basic FY 2024 · Dec 31, 2023 −$3.15
Sga Expense FY 2024 · Dec 31, 2024 $49.08M
Sga Expense FY 2024 · Dec 31, 2023 $50.4M
Rd Expense FY 2024 · Dec 31, 2024 $145.45M
Rd Expense FY 2024 · Dec 31, 2023 $113.3M
Net Income FY 2024 · Dec 31, 2024 −$134.41M
Net Income FY 2024 · Dec 31, 2023 −$112.64M
Operating Income FY 2024 · Dec 31, 2024 −$159.53M
Operating Income FY 2024 · Dec 31, 2023 −$151.1M
Revenue FY 2024 · Dec 31, 2024 $35M
Revenue FY 2024 · Dec 31, 2023 $12.6M